Concepedia

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease

Erwin Dreesen, Filip Baert, David Laharie, Peter Bossuyt, Yoram Bouhnik, Anthony Buisson, Guy Lambrecht, Édouard Louis, Bas Oldenburg, Benjamin Pariente,

Clinical Gastroenterology and Hepatology · 2019 · 85 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch et al. · New England Journal of Medicine · 2010 · 3.1K citations · Full text

, , +14

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

, , +17

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease

Paul Rutgeerts, Brian G. Feagan, Gary R. Lichtenstein et al. · Gastroenterology · 2004 · 948 citations

, , +12

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Jean‐Frédéric Colombel, Remo Panaccione, Peter Bossuyt et al. · The Lancet · 2017 · 912 citations

, , +3

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

Geert D’Haens, Marc Ferrante, Séverine Vermeire et al. · Inflammatory Bowel Diseases · 2012 · 811 citations · Full text

, , +17